Endonovo Therapeutics, Inc. (ENDV) stock
ENDVOTCElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Financials through Q3 FY2023, quarter ended Sep 30, 2023Last filing: 10-Q/A on Dec 29, 2023
$0.00+0.00 (0.00%)
Close on Oct 19, 2026Market cap $135.08KP/E –Yield –
Endonovo Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Endonovo Therapeutics's operating income for the twelve months ending Sep 30, 2023 was -$2.62M. For fiscal 2022 it was -$3.26M. The highest annual figure on record is -$77.99K in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | -$3.26M | – |
| FY2021 | Dec 31, 2021 | -$2.23M | – |
| FY2020 | Dec 31, 2020 | -$2.91M | – |
| FY2019 | Dec 31, 2019 | -$3.81M | – |
| FY2018 | Dec 31, 2018 | -$4.16M | – |
| FY2017 | Dec 31, 2017 | -$4.60M | – |
| FY2016 | Dec 31, 2016 | -$5.41M | – |
| FY2015 | Dec 31, 2015 | -$2.56M | – |
| FY2014 | Dec 31, 2014 | -$2.19M | – |
| FY2013 | Dec 31, 2013 | -$2.43M | – |
| FY2012 | Dec 31, 2012 | -$1.74M | – |
| FY2011 | Dec 31, 2011 | -$95.52K | – |
| FY2010 | Dec 31, 2010 | -$77.99K | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2023 | Sep 30, 2023 | -$472.80K | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -$529.29K | – |
| Q4 FY2022 | Dec 31, 2022 | -$483.05K | – |
| Q3 FY2022 | Sep 30, 2022 | -$496.78K | – |
| Q2 FY2022 | Jun 30, 2022 | -$1.80M | – |
| Q1 FY2022 | Mar 31, 2022 | -$485.76K | – |
| Q4 FY2021 | Dec 31, 2021 | -$373.79K | – |
| Q3 FY2021 | Sep 30, 2021 | -$692.26K | – |
| Q2 FY2021 | Jun 30, 2021 | -$570.05K | – |
| Q1 FY2021 | Mar 31, 2021 | -$590.44K | – |
| Q4 FY2020 | Dec 31, 2020 | -$683.96K | – |
| Q3 FY2020 | Sep 30, 2020 | -$946.80K | – |
| Q2 FY2020 | Jun 30, 2020 | -$601.83K | – |
| Q1 FY2020 | Mar 31, 2020 | -$679.61K | – |
| Q4 FY2019 | Dec 31, 2019 | -$730.00K | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.29M | – |
| Q2 FY2019 | Jun 30, 2019 | -$974.82K | – |
| Q1 FY2019 | Mar 31, 2019 | -$813.00K | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.03M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.04M | – |
| Q2 FY2018 | Jun 30, 2018 | -$816.66K | – |
| Q1 FY2018 | Mar 31, 2018 | -$1.28M | – |
| Q4 FY2017 | Dec 31, 2017 | -$832.96K | – |
| Q3 FY2017 | Sep 30, 2017 | -$1.04M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.18M | – |
| Q1 FY2017 | Mar 31, 2017 | -$557.51K | – |
| Q4 FY2016 | Dec 31, 2016 | -$632.81K | – |
| Q1 FY2016 | Jun 30, 2016 | -$3.47M | – |
| Q1 FY2015 | Mar 31, 2015 | -$431.63K | – |
| Q4 FY2014 | Dec 31, 2014 | -$170.55K | – |
| Q3 FY2014 | Sep 30, 2014 | -$627.18K | – |
| Q2 FY2014 | Jun 30, 2014 | -$826.36K | – |
| Q1 FY2014 | Mar 31, 2014 | -$567.12K | – |
| Q4 FY2013 | Dec 31, 2013 | -$493.98K | – |
| Q3 FY2013 | Sep 30, 2013 | -$427.82K | – |
| Q2 FY2013 | Jun 30, 2013 | -$481.60K | – |
| Q1 FY2013 | Mar 31, 2013 | -$1.03M | – |
See a number that looks wrong?